DMP estimates that the market for treating GBM patients post front-line therapy exceeds US$200 million annually in North America.
OneMedForum to Highlight the Newest, Most Promising Med Tech Innovations
OneMedPlace announced that it will showcase to investors and entrepreneurs the newest and most promising new medical technologies in the region.
Defining a Radiation Target with Augmenix
The company’s SpaceOAR System is designed to temporarily separate organs during radiotherapy so that normal tissues are spared, and to mark tumor resection sites to allow for targeted therapy.
New Test May Predict Risk of Breast Cancer Metastasis
Center have created a test that could help doctors identify which breast cancer patients need aggressive therapy. The study, published in the online version of Clinical Cancer Research, could prevent many women from undergoing unnecessary chemotherapy or radiation treatment.
